SCHEMBL6790520

SCHEMBL6790520

COc1cc(NC(=O)/C=C(/C)c2ccc(C3CCCCC3)cc2)c(C(=O)O)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 1/20 0.49
KDM4E B2RXH2 4/20 0.49
MAPT P10636 3/20 0.47
SERPINE1 P05121 1/20 0.47
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RCE1 Q9Y256 1/20 0.43
AKR1C4 P17516 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GFER P55789 1/20 0.42
MCHR1 Q99705 6/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784789 0.82 SERPINE1 (0.53) KDM4ESERPINE1HSD17B10TERT
SCHEMBL6791397 0.78 MAPT (0.52) LTB4RKDM4EMAPTMAPK1ALDH1A1
SCHEMBL4028323 0.78 KDM4E (0.60) LTB4RKDM4EMAPTMAPK1ALDH1A1
SCHEMBL6791458 0.77 LTB4R (0.51) LTB4RKDM4EMAPTMAPK1ALDH1A1
SCHEMBL6786628 0.77 TERT (0.58) LTB4RKDM4EMAPTALDH1A1HSD17B10
SCHEMBL4021468 0.77 TERT (0.71) LTB4RKDM4EMAPTMAPK1ALDH1A1
SCHEMBL4904913 0.76 HIF1A (0.56) KDM4EMAPTMAPK1ALDH1A1HSD17B10
SCHEMBL6786854 0.76 TERT (0.57) LTB4RKDM4EMAPTMAPK1ALDH1A1
SCHEMBL6792144 0.75 MAPT (0.49) LTB4RKDM4EMAPTMAPK1ALDH1A1
SCHEMBL6785190 0.75 KDM4E (0.51) LTB4RKDM4EMAPTMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 LTB4R 3433/4885KDM4E 1243/4885MAPT 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.